Atezolizumab Does Not Demonstrate Significant OS Benefit Over Chemotherapy in Untreated Locally Advanced or Metastatic Urothelial CancerFebruary 26th 2023
Atezolizumab did not yield a significant improvement in overall survival compared with placebo plus platinum-based chemotherapy and gemcitabine in patients with untreated locally advanced or metastatic urothelial cancer.
Pembrolizumab Shows Antitumor Activity at 45-Month Follow-Up in BCG-Unresponsive Papillary NMIBCFebruary 25th 2023
Patients with papillary high-risk non-muscle-invasive bladder cancer whose disease was BCG-unresponsive showed continued antitumor activity with pembrolizumab monotherapy.
Adjuvant Nivolumab Continues to Minimize Recurrence for Patients With Muscle-Invasive Urothelial CancerFebruary 21st 2023
Extended follow-up of the CheckMate 274 trial showed continued efficacy with nivolumab in patients with muscle-invasive urothelial cancer who had undergone radical resection.
Real-World Data Supports Front-Line Maintenance With Avelumab For Locally Advanced, Metastatic Urothelial CarcinomaFebruary 20th 2023
Real-world data support front-line maintenance with avelumab for patients with locally advanced or metastatic urothelial carcinoma following platinum-based chemotherapy.
Long-Term Tolerability Reported With Darolutamide Use in Patients With Nonmetastatic CRPCFebruary 18th 2023
Approximately 30% of patients remained on treatment with darolutamide for over 4 years, according to a long-term safety and tolerability updated from the ARAMIS rollover study.
Talazoparib/Enzalutamide Improves Imaging-Based PFS in Metastatic CRPC, Regardless of HRR StatusFebruary 17th 2023
At a median follow-up of 24.9 months, imaging-based progression-free survival was not reached among patients with metastatic castration-resistant prostate cancer who had received talazoparib plus enzalutamide.
5-Year Follow-Up Confirms Health-Related QOL Benefit With Nivolumab/Ipilimumab in Advanced RCCFebruary 25th 2022
The immunotherapy combination of nivolumab and ipilimumab elicited favorable health-related quality of life responses compared with sunitinib in patients with advanced renal cell carcinoma.
Nivolumab/Ipilimumab Efficacy in Clear Cell RCC May Be Tied to Certain Immune-Cell Related ParametersFebruary 22nd 2022
Patients with 4-1BB or LAG-3–expressing T cells at baseline, or a high proportion of PD-L1–expressing myeloid cells and plasmacytoid dendritic cells during boost cycles, may be more likely to benefit from the combination of nivolumab and ipilimumab.
Pembrolizumab Plus Sacituzumab Govitecan Yields Encouraging Antitumor Activity in Metastatic Urothelial CancerFebruary 22nd 2022
Adding sacituzumab govitecan to second-line pembrolizumab garnered promising antitumor activity among patients with checkpoint inhibitor–naïve metastatic urothelial cancer.